July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Retinal toxicity in rabbits administered intravitreal TSG-6-rabbit FAb fusion proteins
Author Affiliations & Notes
  • Steven Thomas Laing
    Safety Assessment, Genentech Inc., South San Francisco, California, United States
  • Devin Tesar
    Drug Delivery, Genentech, South San Francisco, California, United States
  • Susan Crowell
    PTPK, Genentech, South San Francisco, California, United States
  • Julia Gray
    BCP, Genentech, South San Francisco, California, United States
  • Kelly Loyet
    BCP, Genentech, South San Francisco, California, United States
  • Roxanne Andaya
    Safety Assessment, Genentech Inc., South San Francisco, California, United States
  • Aija McKenzie
    Safety Assessment, Genentech Inc., South San Francisco, California, United States
  • Florence Lorget
    Safety Assessment, Genentech Inc., South San Francisco, California, United States
  • Bob Kelley
    Drug Delivery, Genentech, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Steven Laing, Genentech Inc. (E); Devin Tesar, Genentech Inc. (E); Susan Crowell, Genentech (E); Julia Gray, Genentech Inc. (E); Kelly Loyet, Genentech Inc. (E); Roxanne Andaya, Genentech Inc. (E); Aija McKenzie, Genentech Inc. (E); Florence Lorget, Genentech Inc. (E); Bob Kelley, Genentech Inc. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 216. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Steven Thomas Laing, Devin Tesar, Susan Crowell, Julia Gray, Kelly Loyet, Roxanne Andaya, Aija McKenzie, Florence Lorget, Bob Kelley; Retinal toxicity in rabbits administered intravitreal TSG-6-rabbit FAb fusion proteins. Invest. Ophthalmol. Vis. Sci. 2018;59(9):216.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Hyaluronic acid binding protein-antibody fragment fusions (HABP-FAb) are designed to have increased residence time in the vitreous chamber compared to FAbs and may provide a platform for long-acting delivery of biologic therapeutics. We aimed to characterize the intravitreal (IVT) safety profile of a species-matched, non-targeted HABP-FAb, TSG6-RabFab, in the New Zealand White rabbit (NZW).

Methods : Three male NZW were administered a single IVT dose of 2 mg/eye 1x-TSG6-RabFab (1:1 ratio) bilaterally. The animals were assessed by serial ocular exam, serum toxicokinetics (TK) and anti-drug-antibodies (ADA), and eyes were examined microscopically (H&E and immunohistochemistry for GFAP, vimentin, and Ki67) at day 30. Subsequently, four male NZW were administered a single IVT dose of 2.5 mg/eye Alexa Fluor 488 (AF488) labeled 2x-TSG6-RabFab (2:1 ratio) bilaterally. In addition to the parameters above, ocular test article (TA) concentration was assessed via fluorophotometer (FPT). The eyes of two animals were examined day 8 and day 30 each for H&E histopathology (OD) and distribution of TA in frozen sections by fluorescence microscopy (FM) (OS).

Results : Serum TK confirmed exposure in all dosed animals. Mild to severe inflammation was noted from day 15 in all animals in both studies and posterior cataracts were noted from day 3 in NZW administered AF488-TSG6-RabFab. Inflammation was associated with high ADA titers (up to 5.82; log10 of last serum dilution above the cutpoint), which were first detectable on day 8, and correlated to the microscopic finding of mononuclear inflammatory cell infiltrates in the ciliary body and posterior segment. Outer retinal degeneration of varying severity and hypertrophy and peripheral migration of Müller cells (vimentin, GFAP and Ki67 positive) were present in all animals at both day 8 and 30. Presence of TA in the vitreous chamber up to day 8 was confirmed by FPT and FM. Assessment of retinal distribution was hampered due to poor morphology in frozen sections.

Conclusions : Retinal degeneration following administration of IVT TSG6-RabFab precludes further development of TSG6 fusions. The role of immunogenicity in the pathogenesis of this finding despite the species-matched Fab moiety, previously been shown to be non-immunogenic in NZW, remains incompletely understood. However, it is concerning that protein-Human Fab fusions may be similarly immunogenic in patients.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×